He Tao, Yang Wenhao, Zhang Xinyi, Li Ping, Yang Dandan, Wu Yunhao, Fan Yuan, Xiang Mengya, Huang Qianqian, Chen Jing, Zhou Runke, Lv Qing, Chen Jie
Department of Breast Surgery, West China Hospital/West China School of Medicine.
Department of Pediatrics, West China Second Hospital/West China School of Medicine.
Medicine (Baltimore). 2020 Jan;99(2):e18550. doi: 10.1097/MD.0000000000018550.
Adjuvant endocrine therapy is a vital portion of postoperative comprehensive treatment for breast cancer patients. In recent years, studies have shown that endocrine therapy has a certain impact on the serum lipids of breast cancer patients, and the changes of lipid profiles may bring a series of problems. However, very few studies focus on this issue to date. The results of these studies are inconsistent, and the influence of different adjuvant endocrine modalities on lipid profiles still remains controversial. In order to better explore this issue, we conduct this network meta-analysis.
The protocol followed preferred reporting items for systematic reviews and meta-analyses protocols. Three main databases (PubMed, Embase, and the Cochrane Library) will be searched systematically for eligible randomized controlled trials without language restriction. In addition, a manual search of the references of relevant published studies will also be considered. Two reviewers will conduct studies selection, data extraction, and risk of bias assessment independently. The primary outcome is the variation of biochemical parameters - the serum lipid profiles (cholesterol, triglyceride, high-density lipoprotein, low low-density lipoprotein).
The results will provide useful information about the side effects of different adjuvant endocrine drugs on lipid profiles in postoperative breast cancer patients (estrogen receptor-positive and/or progesterone receptor-positive).
The findings of this study will be published in a peer-reviewed journal.
CRD42019129850.
辅助内分泌治疗是乳腺癌患者术后综合治疗的重要组成部分。近年来，研究表明内分泌治疗对乳腺癌患者的血脂有一定影响，血脂谱的变化可能带来一系列问题。然而，迄今为止很少有研究关注这个问题。这些研究结果不一致，不同辅助内分泌治疗方式对血脂谱的影响仍存在争议。为了更好地探讨这个问题，我们进行了这项网状Meta分析。
本方案遵循系统评价和Meta分析方案的首选报告项目。将系统检索三个主要数据库（PubMed、Embase和Cochrane图书馆），以查找符合条件的随机对照试验，无语言限制。此外，还将考虑对相关已发表研究的参考文献进行手工检索。两名评价者将独立进行研究选择、数据提取和偏倚风险评估。主要结局是生化参数的变化——血脂谱（胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白）。
结果将为不同辅助内分泌药物对术后乳腺癌患者（雌激素受体阳性和/或孕激素受体阳性）血脂谱的副作用提供有用信息。
本研究结果将发表在同行评审期刊上。
PROSPERO注册号：CRD42019129850。
